Pfizer's head of digital devices says the industry is close to a 'revolution' in using measures from wearables in clinical ...

Pfizer's anti-GDF-15 antibody ponsegromab was able to achieve weight gain in cancer patients with cachexia – a life-threatening metabolic syndrome caused by the underlying disease with no ...

Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating on October 21. David Risinger ...

Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating yesterday. David Risinger has ...

CEO Albert Bourla, who is under attack from activist investor Starboard Value, got a much-needed victory on Tuesday as Pfizer ...

Pharmaceutical giant Pfizer has agreed to pay $35 million to settle allegations that it unlawfully hindered the sale of Lipitor, a drug prescribed to lower cholesterol, resulting in buyers paying ...

Pfizer won the gratitude of governments and patients alike with the vaccine and its antiviral treatment, Paxlovid. CNN named Bourla CEO of the year in 2021, beating out Alphabet’s Sundar Pichai ...

A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the year A boost from COVID-19 treatment sales helped bush Pfizer to a ...

Pfizer is making strides in the rapidly growing weight management market. The company is committed to developing a franchise around obesity and cachexia treatments. This focus aligns with the ...